SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (date of earliest event reported): May 14, 2009.
BioTime,
Inc.
(Exact
name of registrant as specified in its charter)
|
California
|
1-12830
|
94-3127919
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
1301
Harbor Bay Parkway, Suite 100
Alameda,
California 94502
(Address
of principal executive offices)
(510)
521-3390
(Registrant's
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Statements made in this Report that
are not historical facts may constitute forward-looking statements that are
subject to risks and uncertainties that could cause actual results to differ
materially from those discussed. Such risks and uncertainties include
but are not limited to those discussed in this report and in BioTime's Annual
Report on Form 10-K filed with the Securities and Exchange Commission. Words
such as “expects,” “may,” “will,” “anticipates,” “intends,” “plans,” “believes,”
“seeks,” “estimates,” and similar expressions identify forward-looking
statements.
Section
7 - Regulation FD
Item
7.01 - Regulation FD Disclosure
Section
9-Financial Statements and Exhibits
Item
9.01 Financial Statements and Exhibits.
|
Exhibit Number
|
Description
|
|
|
99.1
|
Press
Release Dated May 14, 2009
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
BIOTIME,
INC.
|
|
|
Date: May
14, 2009
|
By
/s/ Steven A.
Seinberg
|
|
Chief
Financial Officer
|
|
|
Exhibit Number
|
Description
|
|
|
99.1
|
Press
Release Dated May 14, 2009
|
|
Exhibit
99.1
|
BioTime,
Inc.
|
1301
Harbor Bay Parkway
|
|
|
Alameda,
CA 94502
|
||
|
Tel:
510-521-3390
|
||
|
Fax:
510-521-3389
|
||
|
www.biotimeinc.com
|
||
|
www.embryome.com
|
BIOTIME
RAISES $4,000,000 IN EQUITY FINANCING
|
--
|
MAY
RECEIVE AN ADDITIONAL $4,000,000 WITHIN 60 DAYS
|
|
--
|
AN ADDITIONAL
$8,800,000 POSSIBLE BY OCTOBER
2010
|
ALAMEDA, CA, May 14, 2009 – BioTime, Inc. (OTCBB: BTIM)
announced that it has raised $4,000,000 of equity capital through the sale of
2,200,000 common shares and 2,200,000 stock purchase warrants to two private
investors. The warrants entitle the investors to purchase additional
common shares at an exercise price of $2.00 per share and expire on October 31,
2010. In addition, the investors have an option to purchase an
additional 2,200,000 common shares and a like number of warrants for an
additional $4,000,000 on or before July 14, 2009. If the additional
shares and warrants are purchased and if all of the warrants are exercised,
BioTime will receive a total of $16,800,000 through this financing.
Additional
information concerning this financing can be found in BioTime’s Quarterly Report
on Form 10-Q to be filed with the Securities and Exchange Commission, a copy of
which will be available at BioTime’s website www.biotimeinc.com.
About
BioTime, Inc.
BioTime,
headquartered in Alameda, California, is a biotechnology company focused on the
emerging field of regenerative medicine. BioTime's lead product, Hextend®, is a
blood plasma expander used in surgery, emergency trauma treatment and other
applications. Hextend® is
manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by
CJ CheilJedang Corp. under exclusive licensing agreements.
BioTime
markets its stem cell research products through its wholly owned subsidiary
Embryome Sciences,
Inc. which is developing new medical and research products using
embryonic stem cell technology. Additional information about BioTime
can be found on the web at www.biotimeinc.com.
Forward-Looking
Statements
Statements
pertaining to future financial and/or operating results, future growth in
research, technology, clinical development and potential opportunities for the
company and its subsidiary, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by management
constitute forward-looking statements. Any statements that are not historical
fact (including, but not limited to statements that contain words such as
“will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,”) should also
be considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks inherent
in the development and/or commercialization of potential products, uncertainty
in the results of clinical trials or regulatory approvals, need and ability to
obtain future capital, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with the
many uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities and
Exchange Commission filings. The company disclaims any intent or obligation to
update these forward-looking statements.
Contact:
BioTime,
Inc.
Judith
Segall
jsegall@biotimemail.com
510-521-3390,
ext. 301
To
receive ongoing BioTime corporate communications, please click on the following
link to join our email alert list: http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0